Jump to content

J. Keith Joung: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
award
m Adding short description: "American pathologist and molecular biologist" (Shortdesc helper)
Line 1: Line 1:
{{Short description|American pathologist and molecular biologist}}
'''J. Keith Joung''' is an American pathologist and molecular biologist who holds the Robert B. Colvin Endowed Chair in Pathology<ref>{{cite web |title=Keith Joung, MD, PhD, was recognized as the inaugural incumbent of the Robert B. Colvin Endowed Chair in Patholog |url=https://www.massgeneral.org/pathology/news/joung-jan-2020}}</ref> at [[Massachusetts General Hospital]] and is Professor of Pathology at [[Harvard Medical School]].<ref name="massgeneral">{{cite web|url=http://www.massgeneral.org/pathology/research/researchlab.aspx?id=1271|publisher=massgeneral.org|title=Joung Laboratory - Massachusetts General Hospital, Boston, MA|access-date=2016-11-19}}</ref> He is a leading figure in the field of genome editing and has pioneered the development of designer nucleases and sensitive off-target detection methods.<ref>{{cite journal |last1=Nair |first1=Prashant |title=QnAs with Jennifer Doudna |journal=Proceedings of the National Academy of Sciences |date=3 May 2016 |volume=113 |issue=18 |pages=4884–4886 |doi=10.1073/pnas.1605008113 |pmid=27092008 |pmc=4983843 |bibcode=2016PNAS..113.4884N |s2cid=8873309 |doi-access=free }}</ref>
'''J. Keith Joung''' is an American pathologist and molecular biologist who holds the Robert B. Colvin Endowed Chair in Pathology<ref>{{cite web |title=Keith Joung, MD, PhD, was recognized as the inaugural incumbent of the Robert B. Colvin Endowed Chair in Patholog |url=https://www.massgeneral.org/pathology/news/joung-jan-2020}}</ref> at [[Massachusetts General Hospital]] and is Professor of Pathology at [[Harvard Medical School]].<ref name="massgeneral">{{cite web|url=http://www.massgeneral.org/pathology/research/researchlab.aspx?id=1271|publisher=massgeneral.org|title=Joung Laboratory - Massachusetts General Hospital, Boston, MA|access-date=2016-11-19}}</ref> He is a leading figure in the field of genome editing and has pioneered the development of designer nucleases and sensitive off-target detection methods.<ref>{{cite journal |last1=Nair |first1=Prashant |title=QnAs with Jennifer Doudna |journal=Proceedings of the National Academy of Sciences |date=3 May 2016 |volume=113 |issue=18 |pages=4884–4886 |doi=10.1073/pnas.1605008113 |pmid=27092008 |pmc=4983843 |bibcode=2016PNAS..113.4884N |s2cid=8873309 |doi-access=free }}</ref>


Revision as of 14:55, 28 April 2022

J. Keith Joung is an American pathologist and molecular biologist who holds the Robert B. Colvin Endowed Chair in Pathology[1] at Massachusetts General Hospital and is Professor of Pathology at Harvard Medical School.[2] He is a leading figure in the field of genome editing and has pioneered the development of designer nucleases and sensitive off-target detection methods.[3]

Education

In 1987, Joung graduated from Harvard College with a bachelor's degree in biochemical sciences.[4] He received an M.D. from Harvard Medical School and a Ph.D. in genetics from Harvard University.[5]

Career

Joung is most well known for his work in genome editing and has contributed to the development of designer nucleases through protein engineering and assays for off-target detection.[6][7][8] In the mid-2000s, his research was focused on creating zinc finger nuclease tools for biological research and gene therapy.[6] He was the leader and founder of the Zinc Finger Consortium and co-authored a study on Oligomerized Pool Engineering (OPEN), a publicly available strategy for rapidly constructing multi-finger arrays.[9][10]

More recently, he contributed to the development of TAL effector, TALENs, and the RNA-guided CRISPR/Cas9 system. In addition to demonstrating the use of the CRISPR/Cas9 system in vivo through the zebrafish model,[11] he pioneered the creation of tools such as GUIDE-seq and CIRCLE-seq to detect nuclease off-targets within the genome.[7][12] In 2016, his group became one of the first to report engineered high-fidelity CRISPR/Cas9 nucleases (HF1) with no detectable off-target effects.[13]

He is one of the scientific co-founders of Editas Medicine, along with Jennifer Doudna, Feng Zhang, George Church, and David Liu.[14] He is also a co-founder of Verve Therapeutics.[15] He received the Ho-Am Prize in Medicine in 2022.

References

  1. ^ "Keith Joung, MD, PhD, was recognized as the inaugural incumbent of the Robert B. Colvin Endowed Chair in Patholog".
  2. ^ "Joung Laboratory - Massachusetts General Hospital, Boston, MA". massgeneral.org. Retrieved 2016-11-19.
  3. ^ Nair, Prashant (3 May 2016). "QnAs with Jennifer Doudna". Proceedings of the National Academy of Sciences. 113 (18): 4884–4886. Bibcode:2016PNAS..113.4884N. doi:10.1073/pnas.1605008113. PMC 4983843. PMID 27092008. S2CID 8873309.
  4. ^ https://www.asgct.org/about/board-officers/j-keith-joung-md-phd [dead link]
  5. ^ "Center for Computational and Integrative Biology".
  6. ^ a b Wade, Nicholas (28 December 2009). "In New Way to Edit DNA, Hope for Treating Disease". The New York Times.
  7. ^ a b Tsai, Shengdar Q.; Zheng, Zongli; Nguyen, Nhu T.; Liebers, Matthew; Topkar, Ved V.; Thapar, Vishal; Wyvekens, Nicolas; Khayter, Cyd; Iafrate, A. John; Le, Long P.; Aryee, Martin J.; Joung, J. Keith (February 2015). "GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases". Nature Biotechnology. 33 (2): 187–197. doi:10.1038/nbt.3117. PMC 4320685. PMID 25513782.
  8. ^ "CRISPR Researchers Develop Highly Sensitive Method for Identification of Off-Target Effects in Vivo". 12 September 2018.
  9. ^ "The Zinc Finger Consortium | Consortium Members". zincfingers.org. Retrieved 2016-11-19.
  10. ^ Maeder, Morgan L.; Thibodeau-Beganny, Stacey; Osiak, Anna; Wright, David A.; Anthony, Reshma M.; Eichtinger, Magdalena; Jiang, Tao; Foley, Jonathan E.; Winfrey, Ronnie J.; Townsend, Jeffrey A.; Unger-Wallace, Erica; Sander, Jeffry D.; Müller-Lerch, Felix; Fu, Fengli; Pearlberg, Joseph; Göbel, Carl; Dassie, Justin P.; Pruett-Miller, Shondra M.; Porteus, Matthew H.; Sgroi, Dennis C.; Iafrate, A. John; Dobbs, Drena; McCray, Paul B.; Cathomen, Toni; Voytas, Daniel F.; Joung, J. Keith (July 2008). "Rapid 'Open-Source' Engineering of Customized Zinc-Finger Nucleases for Highly Efficient Gene Modification". Molecular Cell. 31 (2): 294–301. doi:10.1016/j.molcel.2008.06.016. PMC 2535758. PMID 18657511.
  11. ^ Hwang, Woong Y.; Fu, Yanfang; Reyon, Deepak; Maeder, Morgan L.; Tsai, Shengdar Q.; Sander, Jeffry D.; Peterson, Randall T.; Yeh, J.-R. Joanna; Joung, J. Keith (March 2013). "Efficient genome editing in zebrafish using a CRISPR-Cas system". Nature Biotechnology. 31 (3): 227–229. doi:10.1038/nbt.2501. PMC 3686313. PMID 23360964.
  12. ^ Tsai, Shengdar Q.; Nguyen, Nhu T.; Malagon-Lopez, Jose; Topkar, Ved V.; Aryee, Martin J.; Joung, J. Keith (June 2017). "CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets". Nature Methods. 14 (6): 607–614. doi:10.1038/nmeth.4278. PMC 5924695. PMID 28459458.
  13. ^ Kleinstiver, Benjamin P.; Pattanayak, Vikram; Prew, Michelle S.; Tsai, Shengdar Q.; Nguyen, Nhu T.; Zheng, Zongli; Joung, J. Keith (January 2016). "High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects". Nature. 529 (7587): 490–495. Bibcode:2016Natur.529..490K. doi:10.1038/nature16526. PMC 4851738. PMID 26735016.
  14. ^ "Editas Medicine to develop new class of genome editing therapeutics". 25 November 2013.
  15. ^ "About Us". Verve Therapeutics. Retrieved 5 July 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=J._Keith_Joung&oldid=1085121957"